NKTR-214: Harnessing the IL-2 Pathway in Combination Immunotherapies - a podcast by Pharma Talk Radio

In this podcast, first recorded at the 4th annual IO Combinations 360° conference, Dr Willem Overwijk, Nektar Therapeutics discusses Bempegaldesleukin (NKTR-214): harnessing the IL-2 pathway in combination immunotherapies. Topics include:
Bempegaldesleukin: Structure and function of an engineered IL-2 cytokine prodrug providing sustained IL-2Rβγ-biased signalingPreclinical PK, PD, MOA and combination with PD-1 checkpoint inhibitionClinical PK, PD, clinical response data and biomarkers in patients with melanoma and bladder cancerCombinations under investigation
To learn more about the upcoming IO Combinations 360° conference please visit, www.iocombinations360.com

Further episodes of PharmaTalkRadio

Further podcasts by Pharma Talk Radio

Website of Pharma Talk Radio